Skip to content
TheBrief.Health

Living with HER2 mutations

Stories from people navigating HER2 mutations — diagnosis, treatment, caregiving, and the ordinary days in between.

2 stories

A lung tumor sequencing report highlighting an ERBB2 kinase-domain variant beside a pathology slide.

Oncology

Sevabertinib Approved for HER2-Mutant Nonsquamous NSCLC

Accelerated approval covers previously treated advanced nonsquamous NSCLC with qualifying HER2 tyrosine-kinase-domain activating mutations confirmed by an FDA-approved test.

Rayan Salih · September 30, 2026 · 6 min

Lung tumor specimen beside a genomic sequencing report highlighting an ERBB2 kinase-domain mutation.

Oncology

Sevabertinib Makes HER2 Testing Actionable in NSCLC

The FDA granted accelerated approval to sevabertinib for adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine kinase domain mutations, making validated genomic identification central to treatment selection.

Rayan Salih · 6 min read

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.